GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week
May 03 2017 - 7:30PM
Business Wire
GI Dynamics®, Inc. (ASX:GID), a medical device company that has
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity, announced
that new EndoBarrier data will be presented at Digestive Disease
Week® (DDW), taking place May 6 – 9, 2017 in Chicago, Illinois.
The schedule for the EndoBarrier presentations at DDW is as
follows:
Efficacy and Safety of the EndoBarrier
Gastrointestinal Liner on Obesity and Type 2 Diabetes: A Two Center
Prospective StudyDate & Time: Saturday, May 6
from 12:00 – 2:00pm UTCSession: ASGE Presentation
│BariatricPresenter: Abdulla Alhassani, MD
Augmentation of Meal-Related Symptoms
Following Placement of Duodenal-Jejunal Bypass Sleeve is a
Potential Mechanism of Action Inducing Weight
LossDate & Time: Sunday, May 7 from 12:00 –
2:00pm UTCSession: AGA Presentation │Surgical and Endoscopic
Treatment of ObesityPresenter: Jessica McMaster,
Dietician
Improvements of Liver and Glycemic
Parameters After Duodenal-Jejunal Bypass Sleeve (DJBS)
InsertionDate & Time: Sunday, May 7 from
12:00 – 2:00pm UTCSession: ASGE Presentation │Surgical and
Endoscopic Treatment of ObesityPresenter: Gerald Holtmann,
MD
Effects of the Duodenal-Jejunal Bypass
Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity:
A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal
ChangesDate & Time: Monday, May 8 from 8:30 –
8:45am UTCSession: ASGE Presentation │Surgical and
Endoscopic Treatment of ObesityPresenter: Pichamol
Jirapinyo, MD
Is Re-Implantation of the
Duodenal-Jejunal Bypass Liner Viable?Date &
Time: Monday, May 8 from 10:14 – 10:28am UTCSession: AGA
Presentation │New Bariatric Therapies for Obesity: Surgical and
NonsurgicalPresenter: Jurgen Stein, MD
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically-delivered device therapy approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is approved
and commercially available in multiple countries outside the United
States. EndoBarrier is not approved for sale in the United
States and is limited by federal law to investigational use only in
the United States. Founded in 2003, GI Dynamics is headquartered in
Boston, Massachusetts. For more information, please
visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our development and commercialization plans, potential revenues and
revenue growth, costs, excess inventory, profitability and
financial performance, ability to obtain reimbursement for our
products, clinical trials and associated regulatory submissions and
approvals, the number and location of commercial centers offering
the EndoBarrier, and our intellectual property position. These
forward-looking statements are based on GI Dynamics’ management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks and uncertainties that could cause actual results to
differ materially and adversely from those indicated in or implied
by such forward-looking statements. These risks and uncertainties
include but are not limited to, risks associated with the
consequences of terminating the ENDO trial and the possibility that
future clinical trials will not be successful or confirm earlier
results. Further risks are associated with obtaining funding from
third parties; the timing and costs of clinical trials; the timing
of regulatory submissions; and the timing, receipt and maintenance
of regulatory approvals. The timing and amount of other expenses
and the timing and extent of third-party reimbursement risks
associated with commercial product sales, including product
performance, competition, risks related to market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size
of the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170503006569/en/
GI Dynamics, Inc.United States:Janell Shields,
+1-781-357-3280Investor Relations
Gi Dynamics (ASX:GID)
Historical Stock Chart
From May 2024 to Jun 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Jun 2023 to Jun 2024